Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Coherus Bio (NQ: CHRS )

4.050 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 600
Open 4.050
Bid (Size) 3.960 (1)
Ask (Size) 4.010 (7)
Prev. Close 4.050
Today's Range 4.050 - 4.050
52wk Range 3.655 - 10.99
Shares Outstanding 94,468,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of... 
Via Benzinga
Exposures Product Safety
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga

Performance

YTD
-52.41%
-52.41%
1 Month
-19.80%
-19.80%
3 Month
+6.30%
+6.30%
6 Month
-32.50%
-32.50%
1 Year
-55.05%
-55.05%

More News

Read More
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Stock Popped Today
Via The Motley Fool
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Completes Surface Oncology Acquisition
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Stock Was Plunging This Week
Via The Motley Fool
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Analyst Ratings for Coherus BioSciences
Via Benzinga
Coherus BioSciences to Participate at Upcoming September Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
From Surface Oncology, Inc.
Via GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Earnings Preview For Coherus BioSciences
Via Benzinga
10 Analysts Have This to Say About Coherus BioSciences
Via Benzinga
Why Cummins Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
From Coherus BioSciences, Inc.
Via GlobeNewswire
Mark Cuban's Pharmacy Company Lands Deal With Top 10 US Retailer: Here Are The Details
Via Benzinga
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
From Coherus BioSciences, Inc.
Via GlobeNewswire
Cramer Is Still Bullish On AI Company Up 155% YTD: 'I Remain A Buyer'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.